Evidence map›Paper›PMID 32654078›Full record

ReviewRheumatology international2020

Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes.

Efstathios Kastritis, George D Kitas, Dimitrios Vassilopoulos, Georgios Giannopoulos, Meletios A Dimopoulos, Petros P Sfikakis

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?International journal of molecular sciences · 2022
    Review
  9. Review
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Observational
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Efstathios KastritisDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece.ORCID 0000-0001-8191-5832
George D KitasJoint Rheumatology Program, First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, 17 Agiou Thoma Street, 11527, Athens, Greece.ORCID 0000-0002-0828-6176
Dimitrios VassilopoulosJoint Rheumatology Program, First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, 17 Agiou Thoma Street, 11527, Athens, Greece.ORCID 0000-0003-2288-3863
Georgios GiannopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece.ORCID 0000-0002-1590-3267
Meletios A DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens Medical School, Athens, Greece.ORCID 0000-0001-8990-3254
Petros P SfikakisJoint Rheumatology Program, First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens Medical School, 17 Agiou Thoma Street, 11527, Athens, Greece. psfikakis@med.uoa.gr.ORCID 0000-0001-5484-2930
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence regarding the risk and outcome of COVID-19 in patients with systemic autoimmune diseases. Thus far there is no convincing evidence that any disease-modifying anti-rheumatic drug (conventional synthetic, biologic or targeted synthetic) including hydroxychloroquine, may protect against severe COVID-19 infection; answers about their possible usefulness in the management of the cytokine storm associated with severe COVID-9 infection will only arise from ongoing randomized controlled trials. Evidence on COVID-19 risk and outcome in patients with systemic autoimmune diseases is extremely limited; thus, any conclusions would be unsafe and should be seen with great caution. At present, the risk and severity (hospitalization, intensive care unit admission and death) of COVID-19 infection in people with autoimmune diseases do not appear particularly dissimilar to the general population, with the possible exception of hospitalization in patients exposed to high glucocorticoid doses. At this stage it is impossible to draw any conclusions for differences in COVID-19 risk and outcome between different autoimmune diseases and between the various immunomodulatory therapies used for them. More research in the field is obviously required, including as a minimum careful and systematic epidemiology and appropriately controlled clinical trials.

Indexed as

Antibodies, Monoclonal, HumanizedAntirheumatic AgentsAutoimmune DiseasesBetacoronavirusComorbidityCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeHumansJanus Kinase InhibitorsPandemicsPneumonia, ViralRisk FactorsSARS-CoV-2Severity of Illness IndexAntibodies, Monoclonal, HumanizedAntirheumatic AgentsJanus Kinase InhibitorstocilizumabTumor Necrosis Factor InhibitorsAnti-rheumatic drugsAutoimmune diseasesCovid-19Hydroxychloroquine

Identifiers

PMID32654078
PMCPMC7353833
OpenAlexW3041054432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.